Tags

Type your tag names separated by a space and hit enter

Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Clin Microbiol Infect. 2006 May; 12 Suppl 3:2-11.CM

Abstract

Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality worldwide. The treatment of CAP has been complicated by several factors, including the expanding spectrum of causative organisms and the rising prevalence of antibiotic resistance among respiratory pathogens. Initial antimicrobial treatment for patients with CAP is usually selected empirically and should provide appropriate coverage against the most common causative organisms, including resistant strains. Respiratory fluoroquinolones, such as levofloxacin, are the only antimicrobials that are highly active against the pathogens most frequently implicated in CAP, including macrolide-resistant and penicillin-resistant pneumococci, Haemophilus influenzae, Legionella spp., and atypical agents. This paper reviews recent studies involving adult patients with CAP that suggest that levofloxacin, as compared with other conventional antibiotic treatments, may be associated with better clinical outcomes.

Authors+Show Affiliations

Infectious Disease Service, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, Barcelona, Spain. jcarratala@ub.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16669924

Citation

Carratalá, J, et al. "Clinical Experience in the Management of Community-acquired Pneumonia: Lessons From the Use of Fluoroquinolones." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 12 Suppl 3, 2006, pp. 2-11.
Carratalá J, Martín-Herrero JE, Mykietiuk A, et al. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Clin Microbiol Infect. 2006;12 Suppl 3:2-11.
Carratalá, J., Martín-Herrero, J. E., Mykietiuk, A., & García-Rey, C. (2006). Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 12 Suppl 3, 2-11.
Carratalá J, et al. Clinical Experience in the Management of Community-acquired Pneumonia: Lessons From the Use of Fluoroquinolones. Clin Microbiol Infect. 2006;12 Suppl 3:2-11. PubMed PMID: 16669924.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. AU - Carratalá,J, AU - Martín-Herrero,J E, AU - Mykietiuk,A, AU - García-Rey,C, PY - 2006/5/4/pubmed PY - 2006/6/16/medline PY - 2006/5/4/entrez SP - 2 EP - 11 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 12 Suppl 3 N2 - Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality worldwide. The treatment of CAP has been complicated by several factors, including the expanding spectrum of causative organisms and the rising prevalence of antibiotic resistance among respiratory pathogens. Initial antimicrobial treatment for patients with CAP is usually selected empirically and should provide appropriate coverage against the most common causative organisms, including resistant strains. Respiratory fluoroquinolones, such as levofloxacin, are the only antimicrobials that are highly active against the pathogens most frequently implicated in CAP, including macrolide-resistant and penicillin-resistant pneumococci, Haemophilus influenzae, Legionella spp., and atypical agents. This paper reviews recent studies involving adult patients with CAP that suggest that levofloxacin, as compared with other conventional antibiotic treatments, may be associated with better clinical outcomes. SN - 1198-743X UR - https://www.unboundmedicine.com/medline/citation/16669924/Clinical_experience_in_the_management_of_community_acquired_pneumonia:_lessons_from_the_use_of_fluoroquinolones_ L2 - https://linkinghub.elsevier.com/retrieve/pii/CLM1392 DB - PRIME DP - Unbound Medicine ER -